Neurogene
NGNE
34 hedge funds and large institutions have $45.5M invested in Neurogene in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 7 closing their positions.
19% more capital invested
Capital invested by funds: $38.3M → $45.5M (+$7.13M)
0.19% less ownership
Funds ownership: 3.77% → 3.58% (-0.19%)
6% less funds holding
Funds holding: 36 → 34 (-2)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$413K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$373K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$276K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$109K |
| 5 |
Charles Schwab
San Francisco,
California
|
+$42.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$1.54M |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$474K |
| 3 |
D.E. Shaw & Co
New York
|
-$450K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$160K |
| 5 |
JP Morgan Chase
New York
|
-$144K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citadel Advisors
Miami,
Florida
| $30K | -$66.9K | -1,324 | -71% |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $13K | +$1.87K | +37 | +18% |
|
28
Citigroup
New York
| $13K | +$12.6K | +250 | New |
|
|
CG
29
Cutler Group
San Francisco,
California
| $8K | – | – | – |
|
30
Group One Trading
Chicago,
Illinois
| $7K | -$57.1K | -1,129 | -90% |
|
|
TC
31
Truvestments Capital
Sarasota,
Florida
| $7K | +$6.32K | +125 | New |
|
32
Morgan Stanley
New York
| $4K | +$1.82K | +36 | +95% |
|
33
Bank of Montreal
Toronto,
Ontario, Canada
| $3K | – | – | – |
|
34
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $3K | +$3.03K | +60 | New |
|
|
AFM
35
Anson Funds Management
Dallas,
Texas
| – | -$474K | -10,970 | Closed |
|
|
GCP
36
GSA Capital Partners
London,
United Kingdom
| – | -$160K | -3,711 | Closed |
|
|
PAM
37
Panagora Asset Management
Boston,
Massachusetts
| – | -$96K | -2,230 | Closed |
|
|
KM
38
Kalos Management
Alpharetta,
Georgia
| – | -$36K | -758 | Closed |
|
39
Barclays
London,
United Kingdom
| – | -$21K | -480 | Closed |
|
40
UBS Group
Zurich,
Switzerland
| – | -$1K | -19 | Closed |
|
NGNE Hedge Fund Activity: Q1 2019 in Review
34 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q1 2019, worth a combined $45.5M — up 19% from $38.3M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of NGNE and 5 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 9 added.
The largest buyer was Renaissance Technologies, adding an estimated $413K. The largest seller was Highbridge Capital Management, cutting an estimated $1.54M.
- 34 institutional investors held Neurogene (NGNE) as of Q1 2019, down from 36 in Q4 2018.
- Funds reported $45.5M of Neurogene stock for Q1 2019, up 19% quarter-over-quarter.
- 5 funds opened new Neurogene positions in Q1 2019 and 7 closed out, a net change of -2 holders.
- The largest Neurogene buyer in Q1 2019 was Renaissance Technologies, an estimated $413K added.
- The largest Neurogene seller in Q1 2019 was Highbridge Capital Management, an estimated $1.54M sold.
Based on aggregated 13F filings for Q1 2019.